SCHEMBL4924433

SCHEMBL4924433

O=C(Nc1ccc(N2CCCCC2)nc1)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 2/20 0.57
KCNQ2 O43526 2/20 0.57
MAPT P10636 5/20 0.57
KDM4E B2RXH2 1/20 0.57
CNR1 P21554 6/20 0.56
HRH3 Q9Y5N1 1/20 0.52
RAB9A P51151 3/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
KMT2A Q03164 1/20 0.49
CNR2 P34972 2/20 0.47
FAAH O00519 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
P2RY1 P47900 1/20 0.47
POLB P06746 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
ATF1 P18846 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920815 0.90 MAPT (0.69) KCNQ3KCNQ2MAPTKDM4ECNR1
SCHEMBL4919397 0.89 CNR1 (0.62) KCNQ3KCNQ2MAPTKDM4ECNR1
SCHEMBL4912636 0.81 MAPT (0.59) KCNQ3KCNQ2MAPTKDM4ELMNA
SCHEMBL4924716 0.80 KCNQ3 (0.57) KCNQ3KCNQ2MAPTKDM4ERAB9A
SCHEMBL5185910 0.79 SMN1; SMN2 (0.56) KCNQ3KCNQ2MAPTKDM4ECNR1
SCHEMBL24645772 0.78 MAPT (0.67) KCNQ3KCNQ2MAPTKDM4ERAB9A
SCHEMBL4969527 0.78 KCNQ3 (0.60) KCNQ3KCNQ2MAPTKDM4ERAB9A
SCHEMBL16516259 0.76 CNR1 (0.69) CNR1CNR2FAAH
SCHEMBL27961413 0.75 KCNQ3 (0.56) KCNQ3KCNQ2MAPTKDM4ERAB9A
SCHEMBL22664052 0.75 KCNQ3 (0.54) KCNQ3KCNQ2MAPTKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R KCNQ3 4400/4885KCNQ2 4431/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R KCNQ3 4400/4885KCNQ2 4431/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.